131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

Summary

Tenatumomab is a Sigma-Tau developed new anti-Tenascin antibody. It is a murine monoclonal antibody directed towards Tenascin-C. By means of this antibody, Tenascin-C expression was studied on a commercial tissue array slides each carrying malignant breast, colorectal, lung, ovarian or B and T cell Non-Hodgkin Limphoma tissue sections. All these cancers type showed positivity to Tenascin-C between the 64% and 13.3%. Consequently, Sigma-tau is exploring the use of the 131I-labeled Tenatumomab for anti-cancer radioimmunotherapy.

Timeline

Start

2015-11

Primary completion

2017-04-30

Completion

2017-04-30

Outcome

Outcome not reported

Stopped: “Uptake of drug into the tumour lesion was negligible”

Drugs

Indications